Table 3.
Adjusted change from baseline to EoT in vital signs by sex
| Mean (SE) [95% CI] | |||
|---|---|---|---|
| Combination | Solifenacin 5 mg | Solifenacin 10 mg | |
| Males | n=119 | n=120 | n=114 |
| Systolic blood pressure | |||
| Adjusted change from baseline | 1.82 (0.94) [−0.03 to 3.67] | 1.46 (0.93) [−0.37 to 3.29] | 0.89 (0.96) [−0.99 to 2.78] |
| Difference vs. solifenacin 5 mg | 0.36 (1.32) [−2.23 to 2.95] | ||
| Difference vs. solifenacin 10 mg | 0.92 (1.34) [−1.70 to 3.55] | ||
| Diastolic blood pressure | |||
| Adjusted change from baseline | 1.37 (0.63) [0.14 to 2.61] | 1.10 (0.63) [−0.13 to 2.34] | 0.43 (0.64) [−0.83 to 1.70] |
| Difference vs. solifenacin 5 mg | 0.27 (0.89) [−1.47 to 2.01] | ||
| Difference vs. solifenacin 10 mg | 0.94 (0.90) [−0.82 to 2.71] | ||
| Pulse rate | |||
| Adjusted change from baseline | 0.28 (0.69) [−1.07 to 1.64] | 1.41 (0.69) [0.06 to 2.76] | 0.26 (0.71) [−1.13 to 1.65] |
| Difference vs. solifenacin 5 mg | −1.13 (0.97) [−3.04 to 0.79] | ||
| Difference vs. solifenacin 10 mg | 0.02 (0.99) [−1.91 to 1.96] | ||
| Females | n=587 | n=591 | n=592 |
| Systolic blood pressure | |||
| Adjusted change from baseline | −0.27 (0.42) [−1.10 to 0.55] | −1.41 (0.42) [−2.24 to −0.59] | −1.71 (0.42) [−2.53 to −0.89] |
| Difference vs. solifenacin 5 mg | 1.14 (0.59) [−0.03 to 2.31] | ||
| Difference vs. solifenacin 10 mg | 1.44 (0.59) [0.27 to 2.60] | ||
| Diastolic blood pressure | |||
| Adjusted change from baseline | −0.69 (0.28) [−1.25 to −0.14] | −0.76 (0.28) [−1.32 to −0.21] | −0.66 (0.28) [−1.22 to −0.11] |
| Difference vs. solifenacin 5 mg | 0.07 (0.40) [−0.71 to 0.85] | ||
| Difference vs. solifenacin 10 mg | −0.03 (0.40) [−0.81 to 0.75] | ||
| Pulse rate | |||
| Adjusted change from baseline | 0.50 (0.31) [−0.11 to 1.11] | 0.23 (0.31) [−0.38 to 0.84] | 0.27 (0.31) [−0.33 to 0.88] |
| Difference vs. solifenacin 5 mg | 0.27 (0.44) [−0.59 to 1.13] | ||
| Difference vs. solifenacin 10 mg | 0.23 (0.44) [−0.63 to 1.09] | ||
Adjusted change from baseline values and 95% CIs are generated from ANCOVA model with treatment group, gender, age group, 4‐week incontinence reduction group, geographic region and interaction between age group (<65, ≥65 years) and treatment group as fixed factors and baseline as a covariate.
Differences of adjusted means are calculated by subtracting adjusted mean of solifenacin treatment from adjusted mean of combination treatment.